Activating and inhibitory Fcγ receptors in immunotherapy: Being the actor or being the target

Expert Review of Clinical Immunology

Volumn 5, Issue 6, 2009, Pages 735-747

  Ab̀s, Riad ^a,b   Dutertre, Charles Antoine ^a,c   Agnelli, Lauren ^a   Teillaud, Jean Luc ^a  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b Laboratoire Francais du Fractionnement et des Biotechnologies   (France)

^c INSTITUT COCHIN   (France)

Author keywords

Antibody dependent cell cytotoxicity; Bispecific antibody; Fc fragment; Fc receptor; IgG; Immunomodulation; Monoclonal antibody

Indexed keywords

BISPECIFIC ANTIBODY; CD16 ANTIGEN; CD20 ANTIBODY; CD30 ANTIBODY; CD32 ANTIGEN; CYTOKINE; FC GAMMA RECEPTOR IA; FC GAMMA RECEPTOR IB; FC GAMMA RECEPTOR IIB ANTIBODY; FC GAMMA RECEPTOR IIC; FC GAMMA RECEPTOR IIIA; FC GAMMA RECEPTOR IIIB; FC GAMMA RECEPTOR IV; FC RECEPTOR; FC RECEPTOR IIA; FC RECEPTOR IIB; FUCOSE; GRANZYME B; IMMUNOGLOBULIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD19; MONOCLONAL ANTIBODY FC GAMMA RECEPTOR I; MONOCLONAL ANTIBODY HPA 1A; NEONATAL FC GAMMA RECEPTOR; RHESUS D ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLERGIC DISEASE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; AUTOIMMUNE DISEASE; CLINICAL TRIAL; CROSS LINKING; CYTOKINE RELEASE; DRUG TARGETING; ENDOCYTOSIS; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOMODULATION; IMMUNOTHERAPY; INFLAMMATION; LYMPHOMA; NONHUMAN; PHAGOCYTOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR AFFINITY; REVIEW;

EID: 77949841957     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.09.57     Document Type: Review

References (106)

1. Gessner JE, Heiken H, Tamm A, Schmidt RE. The IgG Fc receptor family. Ann. Hematol. 76(6), 231-248 (1998).
2. Ernst LK, Metes D, Herberman RB, Morel PA. Allelic polymorphisms in the FcgRIIC gene can influence its function on normal human natural killer cells. J. Mol. Med. 80(4), 248-257 (2002).
3. Sibéril S, Dutertre CA, Boix C et al. Molecular aspects of human Fcg R interactions with IgG: functional and therapeutic consequences. Immunol. Lett. 106(2), 111-118 (2006).
4. Ravetch JV, Bolland S. IgG Fc receptors. Annu. Rev. Immunol. 19, 275-290 (2001).
5. Nimmerjahn F, Ravetch JV. Fcg receptors as regulators of immune responses. Nat. Rev. Immunol. 8(1), 34-47 (2008).
6. Amigorena S, Bonnerot C, Drake JR et al. Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes. Science 256(5065), 1808-1812 (1992).
7. Xiang Z, Cutler AJ, Brownlie RJ et al. FcgRIIb controls bone marrow plasma cell persistence and apoptosis. Nat. Immunol. 8(4), 419-429 (2007).
8. Fournier EM, Sibéril S, Costes A et al. Activation of human peripheral IgM+ B cells is transiently inhibited by BCRindependent aggregation of Fcg RIIB. J. Immunol. 181(8), 5350-5359 (2008).
9. Savina A, Amigorena S. Phagocytosis and antigen presentation in dendritic cells. Immunol. Rev. 219, 143-156 (2007).
10. Mantzioris BX, Berger MF, Sewell W, Zola H. Expression of the Fc receptor for IgG (Fcg RII/CDw32) by human circulating T and B lymphocytes. J. Immunol. 150(11), 5175-5184 (1993).
11. Engelhardt W, Matzke J, Schmidt RE. Activation-dependent expression of low affinity IgG receptors Fcg RII(CD32) and Fcg RIII(CD16) in subpopulations of human T lymphocytes. Immunobiol. 192(5), 297-320 (1995).
12. van den Herik-Oudijk IE, Westerdaal NA, Henriquez NV, Capel PJ, van de Winkel JG. Functional analysis of human Fcg RII (CD32) isoforms expressed in B lymphocytes. J. Immunol. 152(2), 574-585 (1994).
13. Cassel DL, Keller MA, Surrey S et al. Differential expression of Fc g RIIA, Fc g RIIB and Fc g RIIC in hematopoietic cells: analysis of transcripts. Mol. Immunol. 30(5), 451-460 (1993).
14. Astier A, de la Salle H, de la Salle C et al. Human epidermal Langerhans cells secrete a soluble receptor for IgG (Fc g RII/CD32) that inhibits the binding of immune complexes to Fc g R+ cells. J. Immunol. 152(1), 201-212 (1994).
15. Gachet C, Astier A, de la Salle H et al. Release of Fc g RIIa2 by activated platelets and inhibition of anti-CD9-mediated platelet aggregation by recombinant Fcg RIIa2. Blood 85(3), 698-704 (1995).
16. Metes D, Gambotto AA, Nellis J et al. Identification of the CD32/FcgRIIc-Q13/ STP13 polymorphism using an allelespecific restriction enzyme digestion assay. J. Immunol. Methods 258(1-2), 85-95 (2001).
17. Dutertre CA, Bonnin-Gélizé E, Pulford K, Bourel D, Fridman WH, Teillaud JL. A novel subset of NK cells expressing high levels of inhibitory FcgRIIB modulating antibody-dependent function. J. Leukoc. Biol. 84(6), 1511-1520 (2008).
18. Li X, Wu J, Carter RH et al. A novel polymorphism in the Fcg receptor IIB (CD32B) transmembrane region alters receptor signaling. Arthritis Rheum. 48(11), 3242-3252 (2003).
19. Ziegler-Heitbrock HW. Heterogeneity of human blood monocytes: the CD14+ CD16+ subpopulation. Immunol. Today 17(9), 424-428 (1996).
20. Schäkel K, Mayer E, Federle C, Schmitz M, Riethmüller G, Rieber EP. A novel dendritic cell population in human blood: one-step immunomagnetic isolation by a specific mAb (M-DC8) and in vitro priming of cytotoxic T lymphocytes. Eur. J. Immunol. 28(12), 4084-4093 (1998).
21. Clémenceau B, Vivien R, Berthomé M et al. Effector memory a b T lymphocytes can express Fcg RIIIa and mediate antibody-dependent cellular cytotoxicity. J. Immunol. 180(8), 5327-5334 (2008).
22. Shibata-Koyama M, Iida S, Misaka H, Mori K et al. Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcgRIIIb and MHC class II expression on the phagocytotic neutrophils. Exp. Hematol. 37(3), 309-321 (2009).
23. García-García E, Nieto-Castañeda G, Ruiz-Saldaña M, Mora N, Rosales C. FcgRIIA and FcgRIIIB mediate nuclear factor activation through separate signaling pathways in human neutrophils. J. Immunol. 182(8), 4547-4556 (2009).
24. Shields RL, Namenuk AK, Hong K et al. High resolution mapping of the binding site on human IgG1 for Fcg RI, Fcg RII, Fcg RIII, and FcRn and design of IgG1 variants with improved binding to the Fcg R. J. Biol. Chem. 276(9), 6591-6604 (2001).
25. Lazar GA, Dang W, Karki S et al. Engineered antibody Fc variants with enhanced effector function. Proc. Natl Acad. Sci. USA 103(11), 4005-4010 (2006).
26. Sibéril S, Dutertre CA, Fridman WH, Teillaud JL. Fcg R: the key to optimize therapeutic antibodies? Crit. Rev. Oncol. Hematol. 62(1), 26-33 (2007).
27. Cartron G, Dacheux L, Salles G et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fcg RIIIa gene. Blood 99(3), 754-758 (2002).
28. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21(21), 3940-3947 (2003).
29. Lejeune J, Thibault G, Ternant D, Cartron G, Watier H, Ohresser M. Evidence for linkage disequilibrium between Fcg RIIIa- V158F and Fcg RIIa-H131R polymorphisms in white patients, and for an Fcg RIIIa-restricted influence on the response to therapeutic antibodies. J. Clin. Oncol. 26(33), 5489-5491 (2008).
30. Weng WK, Levy R. Genetic polymorphism of the inhibitory IgG Fc receptor FcgRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab. Leuk. Lymphoma 50(5), 723-727 (2009).
31. Cartron G, Ohresser M, Salles G, Solal-Céligny P, Colombat P, Watier H. Neutrophil role in in vivo anti-lymphoma activity of rituximab: FCGR3B-NA1/ NA2 polymorphism does not influence response and survival after rituximab treatment. Ann. Oncol. 19(8), 1485-1487 (2008).
32. Stuart SG, Simister NE, Clarkson SB, Kacinski BM, Shapiro M, Mellman I. Human IgG Fc receptor (hFcRII; CD32) exists as multiple isoforms in macrophages, lymphocytes and IgG-transporting placental epithelium. EMBO J. 8(12), 3657-3666 (1989).
33. Lyden TW, Robinson JM, Tridandapani S et al. The Fc receptor for IgG expressed in the villus endothelium of human placenta is FcgRIIb2. J. Immunol. 166(6), 3882-3889 (2001).
34. Cassard L, Cohen-Solal JF, Galinha A et al. Modulation of tumor growth by inhibitory Fc(g) receptor expressed by human melanoma cells. J. Clin. Invest. 110(10), 1549 - 1957 (2002).
35. Cassard L, Cohen-Solal JF, Fournier EM et al. Selective expression of inhibitory Fcg receptor by metastatic melanoma impairs tumor susceptibility to IgG-dependent cellular response. Int. J. Cancer 123(12), 2832-2839 (2008).
36. Mestas J, Hughes CW. Of mice and not men: differences between mouse and human immunology. J. Immunol. 172(5), 2731-2738 (2004).
37. Mechetina LV, Najakshin AM, Alabyev BY, Chikaev NA, Taranin AV. Identification of CD16-2, a novel mouse receptor homologous to CD16/Fc g RIII. Immunogenetics 54(7), 463-468 (2002).
38. Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV. Fcg RIV: a novel FcR with distinct IgG subclass specificity. Immunity 23(1), 41-51 (2005).
39. Mancardi DA, Iannascoli B, Hoos S, England P, Daëron M, Bruhns P. Fcg RIV is a mouse IgE receptor that resembles macrophage FceRI in humans and promotes IgE-induced lung inflammation. J. Clin. Invest. 118(11), 3738-3750 (2008).
40. Takai T, Ono M, Hikida M, Ohmori H, Ravetch JV. Augmented humoral and anaphylactic responses in Fc g RIIdeficient mice. Nature 379(6563), 346-349 (1996).
41. Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV. Fc receptors are required in passive and active immunity to melanoma. Proc. Natl Acad. Sci. USA 95(2), 652-656 (1998).
42. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6(4), 443-446 (2000).
43. Bolland S, Ravetch JV. Spontaneous autoimmune disease in Fc(g)RIIB-deficient mice results from strain-specific epistasis. Immunity 13(2), 277-285 (2000).
44. Bolland S, Yim YS, Tus K, Wakeland EK, Ravetch JV. Genetic modifiers of systemic lupus erythematosus in Fcg RIIB-/- mice. J. Exp. Med. 195(9), 1167-1174 (2002).
45. Huntington ND, di Santo JP. Humanized immune system (HIS) mice as a tool to study human NK cell development. Curr. Top. Microbiol. Immunol. 324, 109-124 (2008).
46. Li M, Wirthmueller U, Ravetch JV. Reconstitution of human FcgRIII cell type specificity in transgenic mice. J. Exp. Med. 183(3), 1259-1263 (1996).
47. Yuasa T, Kubo S, Yoshino T et al. Deletion of Fcg receptor IIB renders H-2(b) mice susceptible to collagen-induced arthritis. J. Exp. Med. 189(1), 187-194 (1999).
48. Fukuyama H, Nimmerjahn F, Ravetch JV. The inhibitory Fcg receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells. Nat. Immunol. 6(1), 99-106 (2005).
49. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291(5503), 484-486 (2001).
50. Desai DD, Harbers SO, Flores M et al. Fcg receptor IIB on dendritic cells enforces peripheral tolerance by inhibiting effector T cell responses. J. Immunol. 178(10), 6217-6226 (2007).
51. Dhodapkar KM, Kaufman JL, Ehlers M et al. Selective blockade of inhibitory Fcg receptor enables dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc. Natl Acad. Sci. USA 102(8), 2910-2915 (2005).
52. Wing MG, Moreau T, Greenwood J et al. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (Fcg RIII) and CD11a/CD18 (LFA-1) on NK cells. J. Clin. Invest. 98(12), 2819-2826 (1996).
53. Greenwood J, Clark M, Waldmann H. Structural motifs involved in human IgG antibody effector functions. Eur. J. Immunol. 23(5), 1098-1104 (1993).
54. Chatenoud L, Bluestone JA. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat. Rev. Immunol. 7(8), 622-632 (2007).
55. Michon J, Moutel S, Barbet J et al. In vitro killing of neuroblastoma cells by neutrophils derived from granulocyte colony stimulating factortreated cancer patients using an antidisialoganglioside anti-Fcg RI bispecific antibody. Blood 86(3), 1124-1130 (1995).
56. Beckman RA, Weiner LM, Davis HM. Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer 109(2), 170-179 (2007).
57. Borghaei H, Alpaugh RK, Bernardo P et al. Induction of adaptive anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): a trial coordinated by the Eastern Cooperative Oncology Group. J. Immunother. 30(4), 455-467 (2007).
58. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346(4), 235-242 (2002).
59. Kumpel BM, Jackson DJ. Characterization and functional activity of human Rh monoclonal antibodies. Transfus. Clin. Biol. 3(6), 453-458 (1996).
60. Kumpel BM, Beliard R, Brossard Y et al. Section 1C: assessment of the functional activity and IgG Fc receptor utilization of 64 IgG Rh monoclonal antibodies. Coordinators report. Transfus. Clin. Biol. 9(1), 45-53 (2002).
61. Glacet A, Ducrot T, Béliard R, Klein P, Bourel D. Anti-Rh(D) monoclonal antibodies: study of their in vitro functional properties. Transfus. Clin. Biol. 3(6), 465-468 (1996).
62. Zalevsky J, Leung IW, Karki S et al. The impact of Fc engineering on an anti-CD19 antibody: increased Fcg receptor affinity enhances B-cell clearing in nonhuman primates. Blood 113(16), 3735-3743 (2009).
63. Reichert JM. Monoclonal antibodies as innovative therapeutics. Curr. Pharm. Biotechnol. 9(6), 423-430 (2008).
64. Umana P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat. Biotechnol. 17(2), 176-180 (1999).
65. Shields RL, Lai J, Keck R et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcg RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277(30), 26733-26740 (2002).
66. Shinkawa T, Nakamura K, Yamane N et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibodydependent cellular cytotoxicity. J. Biol. Chem. 278(5), 3466-3473 (2003).
67. Sibéril S, de Romeuf C, Bihoreau N et al. Selection of a human anti-RhD monoclonal antibody for therapeutic use: impact of IgG glycosylation on activating and inhibitory FcgR functions. Clin. Immunol. 118(2-3), 170-179 (2006)
68. Niwa R, Hatanaka S, Shoji-Hosaka E et al. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 is independent of Fcg RIIIa functional polymorphism. Clin. Cancer Res. 10(18 Pt 1), 6248-6255 (2004).
69. Niwa R, Sakurada M, Kobayashi Y et al. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin. Cancer Res. 11(6), 2327-2336 (2005).
70. de Romeuf C, Dutertre CA, Le Garff-Tavernier M et al. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of Fcg RIIIA/CD16. Br. J. Haematol. 140(6), 635-643 (2008).
71. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N. Engl. J. Med. 345(10), 747-755 (2001).
72. Negi VS, Elluru S, Sibéril S et al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J. Clin. Immunol. 27(3), 233-245 (2007).
73. Debré M, Bonnet MC, Fridman WH et al. Infusion of Fc g fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 342(8877), 945-949 (1993).
74. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313(5787), 670-673 (2006).
75. Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 320(5874), 373-376 (2008).
76. Nimmerjahn F, Ravetch JV. Antiinflammatory actions of intravenous immunoglobulin. Annu. Rev. Immunol. 26, 513-533 (2008).
77. Bruhns P, Samuelsson A, Pollard JW, Ravetch JV. Colony-stimulating factor-1- dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 18(4), 573-581 (2003).
78. Kaneko Y, Nimmerjahn F, Madaio MP, Ravetch JV. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J. Exp. Med. 203(3), 789-797 (2006).
79. Anthony RM, Wermeling F, Karlsson MC, Ravetch JV. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc. Natl Acad. Sci. USA 105(50), 19571-19578 (2008).
80. Bayry J, Bansal K, Kazatchkine MD, Kaveri SV. DC-SIGN and a2,6-sialylated IgG Fc interaction is dispensable for the anti-inflammatory activity of IVIg on human dendritic cells. Proc. Natl Acad. Sci. USA 106(9), E24 (2009).
81. Wright A, Morrison SL. Antibody variable region glycosylation: biochemical and clinical effects. Springer Semin. Immunopathol. 15(2-3), 259-273 (1993).
82. Akilesh S, Petkova S, Sproule TJ, Shaffer DJ, Christianson GJ, Roopenian D. The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. J. Clin. Invest. 113(9), 1328-1333 (2004).
83. Asahi A, Nishimoto T, Okazaki Y et al. Helicobacter pylori eradication shifts monocyte Fcg receptor balance towards inhibitory Fcg RIIB in immune thrombocytopenic purpura patients. J. Clin. Invest. 118(8), 2939-2949 (2008).
84. Ghevaert C, Wilcox DA, Fang J et al. Developing recombinant HPA-1a-specific antibodies with abrogated Fcg receptor binding for the treatment of fetomaternal alloimmune thrombocytopenia. J. Clin. Invest. 118(8), 2929-2938 (2008).
85. Psaila B, Bussel JB. Fc receptors in immune thrombocytopenias: a target for immunomodulation? J. Clin. Invest. 118(8), 2677-2681 (2008).
86. Clarkson SB, Kimberly RP, Valinsky JE et al. Treatment of refractory immune thrombocytopenic purpura with an anti-Fc g-receptor antibody. N. Engl. J. Med. 314(19), 1236-1239 (1986).
87. Ericson SG, Coleman KD, Wardwell K et al. Monoclonal antibody 197 (anti-Fcg RI) infusion in a patient with immune thrombocytopenia purpura (ITP) results in down-modulation of Fcg RI on circulating monocytes. Br. J. Haematol. 92(3), 718-724 (1996).
88. Rankin CT, Veri MC, Gorlatov S et al. CD32B, the human inhibitory Fc-g receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma. Blood 108(7), 2384-2391 (2006).
89. Zhou P, Comenzo RL, Olshen AB et al. CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy. Blood 111(7), 3403-3406 (2008).
90. Veri MC, Gorlatov S, Li H, Burke S et al. Monoclonal antibodies capable of discriminating the human inhibitory Fcg-receptor IIB (CD32B) from the activating Fcg-receptor IIA (CD32A): biochemical, biological and functional characterization. Immunology 121(3), 392-404 (2007).
91. Su K, Yang H, Li X et al. Expression profile of FcgRIIb on leukocytes and its dysregulation in systemic lupus erythematosus. J. Immunol. 178(5), 3272-3280 (2007).
92. Saxon A, Zhu D, Zhang K, Allen LC, Kepley CL. Genetically engineered negative signaling molecules in the immunomodulation of allergic diseases. Curr. Opin Allergy Clin. Immunol. 4(6), 563-568 (2004).
93. Chu SY, Vostiar I, Karki S et al. Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and Fcg RIIb with Fc-engineered antibodies. Mol. Immunol. 45(15), 3926-3933 (2008).
94. Allen LC, Kepley CL, Saxon A, Zhang K. Modifications to an Fcg-Fcvare fusion protein alter its effectiveness in the inhibition of FcvareRI-mediated functions. J. Allergy Clin. Immunol. 120(2), 462-468 (2007).
95. Stahnke B, Thepen T, Stöcker M et al. Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes. Mol. Cancer Ther. 7(9), 2924-2932 (2008).
96. Heijnen IA, van Vugt MJ, Fanger NA et al. Antigen targeting to myeloidspecific human Fcg RI/CD64 triggers enhanced antibody responses in transgenic mice. J. Clin. Invest. 97(2), 331-338 (1996).
97. Kalergis AM, Ravetch JV. Inducing tumor immunity through the selective engagement of activating Fcg receptors on dendritic cells. J. Exp. Med. 195(12), 1653-1659 (2002).
98. Stavenhagen JB, Gorlatov S, Tuaillon N et al. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcg receptors. Cancer Res. 67(18), 8882-8890 (2007).
99. Tedder TF, Baras A, Xiu Y. Fcg receptordependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Springer Semin. Immunopathol. 28(4), 351-364 (2006).
100. Richards JO, Karki S, Lazar GA, Chen H, Dang W, Desjarlais JR. Optimization of antibody binding to FcgRIIa enhances macrophage phagocytosis of tumor cells. Mol. Cancer. Ther. 7(8), 2517-2527 (2008).
101. Bruhns P, Iannascoli B, England P et al. Specificity and affinity of human Fcg receptors and their polymorphic variants for human IgG subclasses. Blood 113(16), 3716-3725 (2009).
102. Ferrara C, Stuart F, Sondermann P, Brünker P, Umana P. The carbohydrate at Fcg RIIIa Asn-162: an element required for high affinity binding to non-fucosylated IgG glycoforms. J. Biol. Chem. 281(8), 5032-5036 (2006).
103. Okazaki A, Shoji-Hosaka1 E, Nakamura K et al. Fucose depletion from human IGG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and Fcg RIIIa. J. Mol. Biol. 336(5), 1239-1249 (2004).
104. Kanda Y, Yamada T, Mori K et al. Comparison of biological activity among non fucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology 17(1), 104-118 (2006).
105. Masuda K, Kubota T, Kaneko E et al. Enhanced binding affinity for Fcg RIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity. Mol. Immunol. 44(12), 3122-3131 (2007).
106. Oganesyan V, Damschroder MM, Leach W, Wu H, DallAcqua WF. Structural characterization of a mutated, ADCCenhanced human Fc fragment. Mol. Immunol. 45(7), 1872-1882 (2008).